Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
caudatin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Caudatin is a C21 steroidal glycoside isolated from plants of the genus Cynanchum. It has been used in traditional medicine and is known for its anticancer properties. Caudatin induces apoptosis in cancer cells by modulating the expression of pro-apoptotic and anti-apoptotic proteins, and it inhibits cell proliferation and migration. It interacts with multiple molecular targets, including uPA, MMP9, and JAK2. Caudatin also inhibits tumor growth in vivo by reducing tumor size and weight.
- Other names
- Caudatin-RM(3β,12β,14β,17α)-12-[[(2E)-3,4-Dimethyl-1-oxo-2-pentenyl]oxy]-3,8,14,17-tetrahydroxypregn-5-en-20-one
02
Targets
BAX (Apoptosis regulator BAX)JAK2 (Janus kinase 2)MMP9 (Matrix metalloproteinase-9)NF-κBTNFAIP1 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 3)CASP3 (Caspase-3)CYCS (Cytochrome c)PLAU (uPA)CASP9 (Caspase-9)
Beyond the preview
Go deeper on caudatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on caudatin.